Intervention

adalimumab

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 34 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials34

Recruiting0

Common conditions10

Lead sponsors shown14

Clinical trials

34 shown

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid ArthritisNCT04230213 · 2020-01-13

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)NCT03737708 · 2019-02-13

Treatment Tapering in JIA With Inactive DiseaseNCT02840175 · 2017-05-18

Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"NCT02878161 · 2016-01-01

A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateNCT02141997 · 2014-07-01

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid ArthritisNCT02092467 · 2014-03-14

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-InhibitorNCT01283971 · 2011-05-01

REstore Working Ability in RheumatoiD ArthritisNCT01405326 · 2011-05-01

Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)NCT01382160 · 2011-01-01

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid ArthritisNCT01225393 · 2010-11-01

Pain Modulation in Rheumatoid Arthritis (RA) - Influence of AdalimumabNCT01197144 · 2010-10-01

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)NCT01185301 · 2010-10-01

A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid ArthritisNCT01162421 · 2010-09-01

Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot StudyNCT00855608 · 2009-03-01

A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical RemissionNCT00808509 · 2009-01-01

A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)NCT00724672 · 2008-09-01

A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid ArthritisNCT01231321 · 2007-12-01

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week DosingNCT00647270 · 2007-12-01

Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid ArthritisNCT00650156 · 2007-06-01

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid ArthritisNCT00420927 · 2006-12-01

Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)NCT00497614 · 2006-05-01

Adalimumab in Adult Japanese Subjects With Rheumatoid ArthritisNCT00235872 · 2004-08-01

Efficacy of HUMIRA in Subjects With Active Rheumatoid ArthritisNCT00234897 · 2004-08-01

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid ArthritisNCT00647491 · 2004-02-01

Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid ArthritisNCT00649922 · 2003-10-01

Post-marketing Observational Study in Subjects With Rheumatoid ArthritisNCT00234884 · 2003-09-01

Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With MethotrexateNCT00647920 · 2003-07-01

Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With MethotrexateNCT00235859 · 2003-07-01

Adalimumab in Adult Japanese Subjects With Rheumatoid ArthritisNCT00235833 · 2003-06-01

Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid ArthritisNCT00234845 · 2003-03-01

A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid ArthritisNCT00448383 · 2002-09-01

Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid ArthritisNCT00650026

APPROVED_FOR_MARKETING

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody AdalimumabNCT00650390

APPROVED_FOR_MARKETING

Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid ArthritisNCT00649545

APPROVED_FOR_MARKETING

Common conditions

Rheumatoid Arthritis27 Arthritis, Rheumatoid3 Choroidal Neovascularization1 Diabetic Retinopathy1 Early Rheumatoid Arthritis1 Fatigue1 Juvenile Idiopathic Arthritis1 Pain1 Rheumatoid Arthritis (RA)1 Uveitis1

Leading sponsors

Abbott 16 AbbVie (prior sponsor, Abbott) 3 AbbVie 2 Pfizer 2 University Hospital, Tours 2 Assistance Publique - Hôpitaux de Paris 1 Astellas Pharma Korea, Inc. 1 Fen Li 1 Genentech, Inc. 1 Hoffmann-La Roche 1 Karolinska Institutet 1 Merck Sharp & Dohme LLC 1 Rafic Hariri University Hospital 1 The Rheumatological Center of Helsinki 1

Trial status mix

COMPLETED26

APPROVED_FOR_MARKETING3

UNKNOWN3

TERMINATED1

WITHDRAWN1

Phase mix

PHASE311

PHASE411

PHASE24

NA2

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.